Oric Pharmaceuticals, Inc. — Director's Dealing 2020

Apr 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2020-04-24

Reporting Person: GORDON CARL L (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-24	Common Stock	P	281250	$16.00	Acquired	281250	Indirect
2020-04-28	Common Stock	C	1875000	—	Acquired	2156250	Indirect
2020-04-28	Common Stock	C	373356	—	Acquired	2529606	Indirect
2020-04-28	Common Stock	C	236111	—	Acquired	2765717	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-28	Series B Preferred Stock	$	C	1875000	Disposed		Common Stock (1875000)	Indirect
2020-04-28	Series C Preferred Stock	$	C	373356	Disposed		Common Stock (373356)	Indirect
2020-04-28	Series D Preferred Stock	$	C	236111	Disposed		Common Stock (236111)	Indirect

Footnotes

F1: The shares are held of record by by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("Advisors") is the managing member of GP VI. By virtue of such relationships, GP VI and Advisors may be deemed to have voting power and investment power over the securities held by OPI VI and as a result, may be deemed to have beneficial ownership over such securities. Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, Sven H. Borho, and Jonathan T. Silverstein, each of whom disclaims beneficial ownership of the shares held by OPI VI.

F2: Each of the Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.